Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093
- 29 February 2008
- journal article
- research article
- Published by Elsevier in Contraception
- Vol. 77 (2) , 84-90
- https://doi.org/10.1016/j.contraception.2007.10.002
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Fat Distribution in Women With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraceptionInternational Journal of Obesity, 2005
- Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetatePublished by Elsevier ,2004
- Hormonal contraception and risk of HIV-1 acquisitionAIDS, 2004
- Injectable Contraceptive Use and Genital Ulcer Disease during the Early Phase of HIV‐1 Infection Increase Plasma Virus Load in WomenThe Journal of Infectious Diseases, 2004
- Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected womenAIDS, 2003
- Pregnancy and progression to AIDS: results of the French prospective cohortsAIDS, 2000
- Does Pregnancy Influence the Course of HIV Infection? Evidence from Two Large Swiss Cohort StudiesObstetrical & Gynecological Survey, 1998
- Does Pregnancy Influence the Course of HIV Infection?JAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Experiences of injectable contraceptive users in an urban settingObstetrics & Gynecology, 1996